Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04458909 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04458909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Terminated
Start date
December 9, 2020
Completion date
August 15, 2023
Enrollment
15 (actual)
Sites
325

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nasopharyngeal carcinoma, metastatic nasopharyngeal keratinizing squamous cell carcinoma, metastatic nasopharyngeal nonkeratinizing carcinoma, metastatic nasopharyngeal undifferentiated carcinoma, nasopharyngeal nonkeratinizing carcinoma, recurrent nasopharyngeal carcinoma, recurrent nasopharyngeal keratinizing squamous cell carcinoma, recurrent nasopharyngeal undifferentiated carcinoma, stage iv nasopharyngeal carcinoma ajcc v8, stage iva nasopharyngeal carcinoma ajcc v8, stage ivb nasopharyngeal carcinoma ajcc v8